2ccPA Study in Patients With Symptomatic Knee Osteoarthritis

Orient Europharma Co., Ltd.40 enrolled

Overview

This clinical trial is designed to determine safety and tolerability as well as the MTD of a single-dose 2ccPA and PK data in symptomatic knee OA.

Osteoarthritis (OA) is a degenerative disease frequently associated with symptoms such as inflammation, stiffness, muscle weakness, joint swollen and joint pain. 2-carba-cyclic phosphatidic acid (2ccPA) is the derivative of natural occurring phospholipid mediator, cyclic phosphatidic acid (cPA). Previous studies suggested that 2ccPA inhibits inflammation and may relieve the pain caused by osteoarthritis. This clinical study aims to assess the safety, tolerability, and pharmacokinetics as well as the maximal tolerated dose (MTD) of a single-dose 2ccPA in symptomatic knee OA. Safety and efficacy data for the design and conduction of subsequent studies will also be collected.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Osteoarthritis (OA) of the Knee

Interventions

2ccPADRUG

Four dose cohorts (50 μg, 200 μg, 800 μg, and 2,400 μg) are planned in this study sequentially. study group: one dose intra-articular on day1

placeboDRUG

A total of 8 subjects will be recruited and randomized in each dose cohort with a 3:1 ratio (6 subjects in the 2ccPA treatment arm and 2 subjects in the placebo arm). control group: one dose intra-articular on day 1

Eligibility

Sex: ALLMin age: 40 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female subjects who are aged between 40 and 75 years old (inclusive) 2. Subjects diagnosed with symptomatic knee OA for at least 6 months prior to study entry (randomization) 3. Subjects whose radiographic evidence of knee OA are classified as grade II or III (according to Kellgren and Lawrence grading system) 4. Subjects with OA knee pain on the majority of days in the past 30 days prior to study entry (randomization). 5. A score of over 8 and below 16 out of 20 for the WOMAC pain subscale in the index knee in screening 6. Male subjects must agree to practice medically acceptable contraceptive regimen (i.e., sterilization surgery, barrier method, abstention) from screening visit until at least 1 month after the study treatment. 7. Subjects who are willing to sign the informed consent form (ICF) 8. Subjects with normal liver and renal function: ALT and AST do not exceed 1.5 ULN (upper limit of normal) Serum Cr levels do not exceed 1.0 ULN Exclusion Criteria: 1. Subjects with known hypersensitivity to study medication 2. Female subjects who are pregnant or lactating. Women of childbearing potential must agree to practice medically acceptable contraceptive regimen from screening visit until at least 1 month after the study treatment and must have a negative urine pregnancy test no earlier than 72 hours prior to study treatment. 3. Intra-articular use of corticosteroid, hyaluronic acid or other intra-articular injection in study knee within 3 months prior to study entry (randomization) 4. Use of chondroitin and/ or glucosamine within 4 weeks prior to study entry (randomization) 5. Subjects with known malignancy 6. History of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, lymphoma, arthritis associated with inflammatory bowel disease, sarcoidosis and amyloidosis 7. Prior arthroscopic or open surgery on the study knee within 6 months prior to study entry (randomization) 8. Clinical signs and symptoms of active knee infection or being treated for knee infection at screening 9. Patients with active inflammation: patients with CRP higher than upper limit of normal range at screening visit will be excluded from the study. 10. Subjects with concurrent medical or arthritic condition that could interfere with evaluation of the index knee joint, including fibromyalgia, based on investigator's clinical judgment 11. More significant pain from the back or the hip than the knee 12. Skin breakdown or lesion on the study knee that is not suitable for injection, based on investigator's discretion 13. Prior knee replacement on the study knee or planned knee replacement during the study period 14. Subjects with (1) meniscus tears which requires repairment surgery OR (2) anterior cruciate ligament rupture based on screening MRI results 15. Patients with known severe synovitis, synovium necrosis in the target knee joint judged by investigator at screening 16. Patients with PT/ APTT higher than the upper limit of normal range at screening 17. History of drug or alcohol dependence in the past 3 years 18. Having known infection with HIV-1, HBV, HCV 19. Use of any investigational drug or participation in any drug study within 4 weeks prior to study entry (randomization) 20. Subjects who are unwilling or unable to comply with study procedures 21. Any clinical condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk to participate in the study or confounds the ability to interpret data from the study as judged by the investigator.

Locations (5)

Veteran General Hospital Taipei

Taipei, Taiwan

Tri-Service General Hospital

Taipei, Taiwan

Mackay Memorial Hospital

Taipei, Taiwan

Kaohsiung Chang Gung Memorial Hospital

Taipei, Taiwan

National Cheng Kung University Hospital

Outcomes

Primary Outcomes

Adverse events will be coded with MedDRA and analyzed by system organ class (SOC) and preferred term. The number of subjects who experience DLT will be calculated at each dose level and the result of MTD will be provided.

To determine safety and tolerability as well as the maximal tolerated dose (MTD) of a single-dose 2ccPA in symptomatic knee OA

Time frame: 85 days

Secondary Outcomes

20% improvement in the The Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain and physical function subscales

Proportion of subjects with a 20% improvement in the WOMAC pain and physical function subscales on Day 2, Day 3, Day 8, Day 15, Day 29 post treatment, compared with placebo group and baseline

Time frame: 85 days

50% improvement in the The Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain and physical function subscales

Proportion of subjects with a 50% improvement in the WOMAC pain and physical function subscales on Day 2, Day 3, Day 8, Day 15, Day 29 post treatment, compared with placebo group and baseline

Time frame: 85 days

70% improvement in the The Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain and physical function subscales

Proportion of subjects with a 70% improvement in the WOMAC pain and physical function subscales on Day 2, Day 3, Day 8, Day 15, Day 29 post treatment, compared with placebo group and baseline

Time frame: 85 days

Maximum plasma concentration (Cmax) of 2ccPA

Pharmacokinetic profile of 2ccPA

Time frame: at baseline (pre-dose), 15 ± 5 minutes, 30 ± 5 minutes, 1 hour ± 10 minutes, 2 hours ± 10 minutes, 4 hours ± 10 minutes, 6 hours ± 10 minutes, 8 hours ± 10 minutes, 12 ± 2 hours, 24 ± 2 hours (Day 2) and 48 ± 2 hours (Day 3) after 2ccPA treatment.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.